The NINDS Small Business Program provides support to small businesses to develop products addressing unmet clinical and research needs.
Here we present nonconfidential company information about a subset of awardees ready to attract third-party collaborators and investors.
Aquilus Pharmaceuticals is a biotech company focused on the treatment and management of amyotrophic lateral sclerosis (ALS), neuropathic pain and other neurological disorders.
AXONIS Therapeutics is advancing breakthrough drug discoveries to develop a pipeline of first-in-class neuron-reviving therapeutics for neurological disorders, to make a real difference for patients, their families, and the global healthcare system.
Dignify Therapeutics, restoring voluntary control of bowel and bladder for people with neurological disorders, diabetes, and the elderly.
Eysz is building an AI-based software platform that uses eye-movement data as input to identify patterns associated with consciousness, cognition, and mood to help doctors and pharma companies measure disease progression and treatment outcomes for neurological disorders starting with epilepsy.
Great Lakes NeuroTechnologies, the leader in remote monitoring of movement disorders, markets KinesiaU™, enabling doctors to provide personalized, efficient, accurate therapy titration with fewer office visits, saving time and money.
Neurexis Therapeutics, Neuroprotective Peptides for Cerebral Ischemia.
NuvOx Pharma, Novel oxygen therapeutics platform to fight fatal diseases.
Palm Therapeutics is leveraging a proprietary drug discovery platform to develop first-in-class cancer therapies.
PathMaker Neurosystems is a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders including stroke and ALS.
PolyCore Thereapeutics, Inc. is a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders.
Rebion is commercializing a breakthrough diagnostic platform technology to definitively identify life-altering conditions that manifest from functional impairments in the brain, including lazy eye and traumatic brain injury.
SNJ Pharma’s SNJ101, the first plasmin-independent thrombolytic agent, aims to revolutionize the treatment of ischemic diseases by addressing the bleeding complications associated with current thrombolytic therapies, providing a therapeutic option for over 200 million patients.
South Rampart Pharma is committed to improving the lives of people suffering from acute, neuropathic and chronic pain by developing a new class of non-opioid pain medicines that do not have the toxicities found in current over the counter and prescription medicines.